HIP 0612
Alternative Names: HIP-0612Latest Information Update: 27 Dec 2022
At a glance
- Originator Hanmi Pharmaceutical
- Class Antiulcers
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Gastric ulcer
Most Recent Events
- 22 Dec 2022 Preclinical trials in Gastric ulcer in South Korea (unspecified route)
- 22 Dec 2022 Hanmi Pharmaceutical Company plans a phase III trial for Gastric ulcer in January 2023 (NCT05656092)